What Is Canagliflozin and How Does It Work?

Canagliflozin is an oral medication approved for the management of type 2 diabetes. It belongs to the class of drugs known as sodium-glucose cotransporter 2 (SGLT2) inhibitors. By blocking the SGLT2 protein in the proximal renal tubule, canagliflozin prevents the reabsorption of filtered glucose back into the bloodstream. Instead, the excess glucose is excreted in the urine—a process called glycosuria. This unique mechanism not only lowers blood glucose levels independent of insulin but also contributes to modest weight loss and reductions in blood pressure. However, the same mechanism that makes the drug effective also predisposes the urinary tract to bacterial overgrowth.

The presence of glucose in the urine provides a rich substrate for microorganisms, particularly Escherichia coli, the most common cause of urinary tract infections (UTIs). Understanding this relationship is essential for both clinicians and patients to minimize the risk of infection while still achieving glycemic control. The U.S. Food and Drug Administration (FDA) has issued specific warnings regarding UTIs with SGLT2 inhibitors, and landmark clinical trials such as CANVAS and CREDENCE have documented elevated infection rates among canagliflozin users. Canagliflozin is typically dosed at 100 mg or 300 mg once daily, with the higher dose producing greater glycosuria but also a marginally higher infection risk.

Beyond glycemic control, canagliflozin has demonstrated benefits in reducing major adverse cardiovascular events and slowing the progression of diabetic kidney disease. These cardiorenal advantages have expanded its use beyond diabetes management into heart failure and chronic kidney disease, even in patients without diabetes. As the patient population broadens, understanding the infection risk profile becomes increasingly important.

Epidemiology of Urinary Tract Infections in Diabetes

Patients with type 2 diabetes already face a higher baseline risk of UTIs compared to the general population. Poor glycemic control, impaired neutrophil function, and increased bacterial adherence to uroepithelial cells all contribute to this vulnerability. Studies estimate that the incidence of UTIs in women with diabetes is two to four times higher than in women without diabetes. The addition of an SGLT2 inhibitor like canagliflozin further amplifies this risk through drug-induced glycosuria.

Clinical trial data from the CANVAS and CREDENCE trials indicate that the absolute risk increase for UTIs with canagliflozin is approximately 1–3% compared to placebo. This translates to roughly one additional UTI per 100 patient-years of treatment. The number needed to harm varies depending on baseline risk factors, but for populations with high baseline susceptibility, the impact can be clinically meaningful. A meta-analysis published in Diabetes Care confirmed a statistically significant increase in both UTIs and genital mycotic infections across the SGLT2 inhibitor class, with canagliflozin showing a slightly higher risk than empagliflozin or dapagliflozin in some comparative analyses.

Urinary Tract Infections: A Deeper Look

Types and Pathogenesis

A urinary tract infection occurs when bacteria enter the urethra and multiply in the urinary system. While UTIs can involve the lower tract (cystitis) or the upper tract (pyelonephritis), the lower tract is most frequently affected in patients taking canagliflozin. The infection typically arises from ascending bacteria, with E. coli responsible for approximately 80% of uncomplicated cases. Other organisms such as Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis are also common. In the presence of glycosuria, these bacteria find an abundant energy source, allowing them to proliferate more rapidly and adhere to the uroepithelium with greater ease. The glycosuric environment also reduces the effectiveness of host immune defenses, such as the antimicrobial activity of urinary oligosaccharides and defensins.

Clinical Presentation

Symptoms of a UTI can range from mild to severe. Typical complaints include:

  • Dysuria—a painful or burning sensation during urination
  • Increased urinary frequency and urgency
  • Cloudy, dark, or foul-smelling urine
  • Pelvic or suprapubic discomfort
  • Feeling of incomplete voiding

When the infection ascends to the kidneys, symptoms may also include fever, chills, flank pain, nausea, and vomiting. Complicated UTIs—those occurring in patients with diabetes or other comorbidities—are more likely to progress to pyelonephritis and even urosepsis, a life-threatening systemic infection. Therefore, early recognition and treatment are essential. Notably, patients with diabetic neuropathy may have blunted pain responses, potentially delaying presentation and increasing the risk of complications.

Differential Diagnosis: UTI Versus Genital Mycotic Infection

SGLT2 inhibitors increase the risk of both UTIs and genital mycotic infections, and the symptoms can overlap. Genital mycotic infections typically present with pruritus, erythema, and discharge in the genital area rather than dysuria or urinary frequency. However, patients may find it difficult to distinguish between the two. Clinicians should perform a focused history and, when uncertainty exists, a urinalysis to guide treatment. Misdiagnosis can lead to inappropriate antibiotic use or inadequate treatment of a fungal infection. Patient education about the distinguishing features of each condition can improve self-reporting and reduce unnecessary clinic visits.

The Evidence Linking Canagliflozin and UTIs

Clinical Trial Data

The CANVAS Program, which integrated data from two large randomized controlled trials, reported an increase in genital mycotic infections and UTIs among participants receiving canagliflozin compared to placebo. Specifically, the risk of UTI was approximately 1.5 times higher in the canagliflozin group. The CREDENCE trial, which evaluated canagliflozin in patients with diabetic kidney disease, also noted a numerically higher incidence of severe UTIs, including pyelonephritis and urosepsis requiring hospitalization. A meta-analysis of SGLT2 inhibitors published in Diabetes, Obesity and Metabolism confirmed that while the absolute risk increase is modest (1–3%), the relative risk for recurrent or complicated UTIs is significant, particularly in women and older adults.

Postmarketing surveillance data have added to this evidence base. The FDA Adverse Event Reporting System (FAERS) has received reports of serious UTIs, including urosepsis and pyelonephritis, in patients taking canagliflozin. These real-world data underscore the importance of ongoing vigilance even after a drug has received regulatory approval.

Mechanism of Increased Susceptibility

Elevated urinary glucose concentration is the primary driver. Glucose in the urine creates a hyperosmolar environment that may impair local immune defenses, such as the activity of neutrophils and the integrity of the uroepithelium. Additionally, glucose can modify the expression of bacterial adhesins, enhancing attachment to bladder walls. Some research suggests that SGLT2 inhibitors may also alter the urinary microbiome, reducing the dominance of protective lactobacilli and allowing pathogenic bacteria to flourish. These changes collectively tip the balance toward infection, especially in individuals with additional risk factors. Furthermore, the osmotic diuresis induced by glycosuria can lead to reduced bladder emptying efficiency, increasing the contact time between bacteria and the uroepithelium.

Who Is at Highest Risk?

Not everyone taking canagliflozin will develop a UTI. However, several factors amplify the risk:

  • Female sex—Women have shorter urethras, making bacterial ascent more likely.
  • History of recurrent UTIs—Prior infections indicate a baseline susceptibility.
  • Poor glycemic control—Higher baseline blood glucose leads to more pronounced glycosuria.
  • Age over 65 years—Age-related immune changes and functional bladder changes increase risk.
  • Catheter use or urinary retention—These provide additional entry points or stagnant urine for bacterial growth.
  • Immunocompromised state—Diabetes itself can impair immune function, and SGLT2 inhibitors may add further burden.

Clinicians should evaluate these factors before prescribing canagliflozin and counsel patients accordingly. For individuals with a strong history of recurrent or complicated UTIs, alternative therapies such as GLP-1 receptor agonists, DPP-4 inhibitors, or insulin may be considered based on individual patient characteristics and glycemic targets. Shared decision-making should incorporate the patient's values and preferences regarding the trade-off between glycemic and cardiorenal benefits and infection risk.

Prevention Strategies for Patients on Canagliflozin

Lifestyle and Hygiene Measures

Simple preventive steps can substantially reduce UTI incidence. Patients should be instructed to:

  • Drink adequate water—Hydration dilutes urine and promotes frequent voiding, flushing bacteria from the urinary tract. Aim for at least 1.5–2 liters of water daily unless contraindicated.
  • Practise good personal hygiene—Wiping from front to back after urination or defecation helps prevent transfer of bacteria from the perineum.
  • Urinate before and after sexual activity—This mechanical flushing reduces the chance of post-coital cystitis.
  • Avoid irritating feminine products—Douches, powders, and sprays can disrupt the natural flora and increase infection risk.
  • Wear breathable cotton underwear and avoid tight-fitting pants to reduce moisture and irritation in the urogenital region.

Medical Management

Patients with recurrent UTIs while on canagliflozin may benefit from:

  • Urine culture and sensitivity testing to identify the specific pathogen and guide antibiotic selection.
  • Low-dose prophylactic antibiotics, such as nitrofurantoin or trimethoprim-sulfamethoxazole, under the guidance of an infectious disease specialist.
  • Cranberry products—Although evidence is mixed, some studies suggest that cranberry proanthocyanidins can inhibit bacterial adhesion to the uroepithelium. The American Urological Association notes limited evidence but does not recommend routine use for UTI prevention in most populations.
  • D-mannose supplements—This naturally occurring sugar can bind to E. coli and help flush it from the urinary tract, though robust clinical data are limited and the quality of available studies is variable.
  • Adjustment of canagliflozin dose or switching to another class of antidiabetic medication if infections persist despite preventive measures. Reducing the dose from 300 mg to 100 mg may lower glycosuria and infection risk, though this decision must be balanced against glycemic targets.

It is critical that any suspected UTI be confirmed by urinalysis and culture rather than treated empirically with antibiotics unless symptoms are severe. Indiscriminate antibiotic use can lead to resistance and complicate future management. Antibiotic stewardship is particularly important in the diabetic population, who may require frequent courses of antibiotics for various infections.

Recognizing and Acting on UTI Symptoms

Patients taking canagliflozin should be educated to recognize early signs of a UTI and seek medical attention promptly. Delayed treatment increases the risk of ascending infection, renal involvement, and systemic complications. The FDA has highlighted cases of urosepsis and pyelonephritis in postmarketing surveillance of SGLT2 inhibitors. Therefore, a low threshold for evaluation is warranted. Healthcare providers should teach patients to watch for:

  • Sudden onset of dysuria or suprapubic discomfort
  • Changes in urine appearance or odor
  • Lower back or flank pain
  • Fever, chills, or general malaise
  • New or worsening confusion in elderly patients

When symptoms are present, a urinalysis with microscopy, dipstick testing for leukocyte esterase and nitrite, and a urine culture should be performed. Empiric antibiotic therapy should follow local antibiogram patterns, with adjustment based on culture results. Most uncomplicated UTIs respond well to a 3–5 day course of nitrofurantoin or a fluoroquinolone, though fluoroquinolones are reserved for complicated cases due to side effects. For pyelonephritis or urosepsis, hospitalization for intravenous antibiotics and supportive care may be necessary. Follow-up urine cultures after treatment are recommended for patients with diabetes to confirm microbiologic cure.

Special Considerations for High-Risk Populations

Elderly Patients

Older adults often have altered immune responses, incomplete bladder emptying, and higher rates of asymptomatic bacteriuria. Canagliflozin should be used with caution in this group. Asymptomatic bacteriuria—the presence of bacteria in the urine without symptoms—is common in older women and does not generally require treatment. However, if symptoms develop, the risk of progression to severe infection is greater. Routine screening for bacteriuria in asymptomatic elderly patients on SGLT2 inhibitors is not recommended, but clinical vigilance is essential. The decision to initiate canagliflozin in an older adult should include a discussion of fall risk from volume depletion and the potential for drug interactions with diuretics.

Patients with Diabetic Kidney Disease

In the CREDENCE trial, patients with chronic kidney disease (estimated glomerular filtration rate 30–90 mL/min/1.73 m²) had a higher incidence of genital infections and UTIs with canagliflozin. The reduced renal function may concentrate the drug in the urine, amplifying glycosuria and potentially increasing infection risk. Dose adjustment is required for renal impairment, and prescribers should monitor for signs of infection more frequently in this subpopulation. Of note, the cardiorenal benefits of canagliflozin are most pronounced in patients with established kidney disease, making the risk-benefit calculus particularly nuanced.

Patients with a History of Genital Mycotic Infections

SGLT2 inhibitors cause a well-documented increase in genital mycotic infections, particularly in women and uncircumcised men. Although these are distinct from UTIs, they share a common risk factor: elevated glucose in the urogenital region. Patients with recurrent yeast infections may also be more prone to UTIs due to altered local immune defenses. Managing fungal infections promptly with topical or oral antifungals can help reduce the overall infectious burden. Patients should be educated about the distinct symptoms of each condition to facilitate appropriate self-treatment and healthcare-seeking behavior.

Monitoring and Follow-Up Care

Patients on canagliflozin should have regular follow-up appointments that include an assessment of urinary symptoms. At each visit, clinicians should ask about dysuria, frequency, urgency, and any changes in urine appearance. For patients with recurrent infections, a referral to urology or infectious disease may be appropriate. Routine urinalysis in asymptomatic patients is not recommended, as asymptomatic bacteriuria is common and does not warrant treatment. However, if a patient develops a febrile UTI or pyelonephritis, a thorough workup to exclude anatomical abnormalities or obstruction should be considered. The frequency of monitoring should be tailored to the individual's risk profile, with higher-risk patients seen more often.

Balancing Benefits and Risks: The Role of Shared Decision-Making

Despite the increased risk of UTIs, canagliflozin offers substantial benefits for patients with type 2 diabetes. It reduces blood glucose, promotes weight loss, lowers blood pressure, and has been shown to reduce the risk of major adverse cardiovascular events and progression of diabetic kidney disease. For many patients, these benefits outweigh the risks of infection, especially when prevention strategies are employed. Discussing the specific risk profile with each patient helps set realistic expectations. The American Diabetes Association’s Standards of Medical Care in Diabetes recommend careful assessment of UTI history before initiating SGLT2 inhibitor therapy and ongoing education about symptoms and hygiene.

Patients and providers should weigh the absolute risk increase—approximately one additional UTI per 100 patient-years of treatment—against the proven cardiorenal benefits. For a patient with established cardiovascular disease or chronic kidney disease, the net clinical benefit strongly favors the use of canagliflozin, even if a mild to moderate UTI occurs. The key is to have a plan in place: early detection, prompt treatment, and, if needed, modification of therapy. Shared decision-making ensures that the patient understands the trade-offs and is an active partner in managing their health. Decision aids, such as visual risk tables or conversation guides, can facilitate this process.

Future Directions and Ongoing Research

Researchers are exploring several avenues to mitigate UTI risk associated with SGLT2 inhibitors. These include the development of more selective SGLT2 inhibitors that may produce less glycosuria, combination therapies with other agents that reduce urinary glucose excretion, and adjunctive treatments such as oral agents that bind urinary glucose or enhance uroepithelial defenses. Additionally, microbiome studies may identify biomarkers that predict which patients are most susceptible to infection, allowing for personalized prescribing. As the class of SGLT2 inhibitors expands—with newer agents like empagliflozin, dapagliflozin, and ertugliflozin—postmarketing data will continue to refine our understanding of infection risk profiles across different drugs and populations.

Clinical trials investigating the use of SGLT2 inhibitors in heart failure and chronic kidney disease in patients without diabetes will provide additional safety data in populations that may have different baseline UTI risks. Ongoing pharmacovigilance and real-world evidence studies will be essential to fully characterize the long-term infection risk and identify optimal risk mitigation strategies.

Conclusion

Canagliflozin is a powerful tool in the management of type 2 diabetes, offering significant glycemic, cardiovascular, and renal benefits. However, its mechanism of action—inducing glycosuria—carries an increased risk of urinary tract infections. Awareness of this risk, recognition of symptoms, and implementation of preventive strategies are essential to maintaining patient safety. With proper education, regular monitoring, and a collaborative approach between patient and healthcare provider, the majority of UTIs can be managed without interrupting the drug’s valuable therapeutic effects. For those who experience recurrent or severe infections, alternative antidiabetic medications remain available. Ultimately, the decision to use canagliflozin should be individualized, balancing the proven advantages with the manageable risk of infection.

For further reading on SGLT2 inhibitors and UTI risk, consult the FDA safety communication regarding SGLT2 inhibitors, the American Diabetes Association Standards of Care, the CANVAS trial results published in the New England Journal of Medicine, and the CREDENCE trial results for diabetic kidney disease.